Authors: David Howett, University of Cambridge, UK
Research led by Svetlana Hakobyan at Cardiff University (UK) examined the potential of developing biomarkers from the innate immune system in the detection of Alzheimer’s disease (AD) in blood samples. The research, published in September 2016 by The Journal of Alzheimer’s Disease, trained and applied a statistical model on a variety of disease states. The apolipoprotein clusterin best predicted progression from mild cognitive impairment (MCI) to AD and differentiated AD from healthy controls (HCs).
Previous attempts to establish plasma biomarkers for assisting the diagnosis of AD have been unsuccessful, yet the successful development of therapeutic interventions aiming to inhibit disease progression from MCI to AD dementia hinges upon early identification. The development of a composite plasma biomarker battery sensitive and specific to AD is desirable due to its objective and economically viable measure of pathology; he development of such a battery will not only improve diagnosis, but will likely inform disease stratification, prognostic trajectory and therapeutic strategy.